Tag
This review synthesizes phase 3 RAPIDe-3 trial results demonstrating oral deucrictibant’s rapid efficacy and safety for hereditary angioedema attacks, contextualized with phase 2 studies and prophylactic applications, highlighting its
Lonvoguran ziclumeran, an in vivo CRISPR-based single-dose gene-editing therapy, significantly reduces hereditary angioedema attacks and demonstrates a favorable safety profile, marking a transformative advance in treatment.
An interim analysis of the KONFIDENT-S open-label extension shows that oral sebetralstat is well tolerated and provides rapid symptom relief for breakthrough attacks in HAE patients on long-term prophylaxis.
EMA endorses sebetralstat, the first oral on-demand therapy for hereditary angioedema, following positive results from the KONFIDENT phase 3 trial, offering a more convenient and rapid treatment option for acute attacks.
